Non-hallucinogenic neuroplastogens offer benefits over classical psychedelics, including simpler delivery, stronger IP protection, and patient tolerability, writes Enveric Biosciences CEO Joseph ...

As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to ...

New treatment paradigms are making biopharma industry stakeholder communications more ambitious and complex. But they must also be credible and consumable, writes Michelle Bridenbaker.

EYs Arda Ural provides an assessment of the current life sciences business environment, and reasons for optimism about 2025 despite the uncertainty that comes with a new administration in the U.S.

Big Pharma incubators offer unique funding and innovation opportunities for emerging biopharma companies, and strong sources of external innovation for incubator host organizations.

When engaging in the bidding process, pharmaceutical manufacturers and medical device companies must match the sophistication of the PBM/GPO entities through careful strategic planning that considers ...

Mental health has become one of the significant factors determining early retirement, disability benefits, absenteeism levels, and high societal costs such as productivity losses and medical treatment ...

Chris Anzalone, CEO of Arrowhead Pharmaceuticals, discusses overcoming adversity while leading the company through challenging times.

We asked John Oyler, an American entrepreneur and the chairman, cofounder, and CEO of BeiGene, why he decided to build a global biopharmaceutical company with roots beginning in China. His answer may ...

By Arjan Singh Conferences and trade shows are great places to learn about your competitive environment, as most companies in the industry usually attend these events; this includes competitors, ...

Matt Patterson, chairman and CEO of Audentes Therapeutics, shares the experiences that prepared him for building the gene therapy company he cofounded into a publicly traded business valued at nearly ...